These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 17549368

  • 1. Differential regulation of the cytotoxicity activity of paclitaxel by orobol and platelet derived growth factor in human ovarian carcinoma cells.
    Isonishi S, Saitou M, Saitou M, Yasuda M, Tanaka T.
    Oncol Rep; 2007 Jul; 18(1):195-201. PubMed ID: 17549368
    [Abstract] [Full Text] [Related]

  • 2. Enhancement of sensitivity to cisplatin by orobol is associated with increased mitochondrial cytochrome c release in human ovarian carcinoma cells.
    Isonishi S, Saitou M, Yasuda M, Ochiai K, Tanaka T.
    Gynecol Oncol; 2003 Aug; 90(2):413-20. PubMed ID: 12893210
    [Abstract] [Full Text] [Related]

  • 3. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, Landoni F, Mayo JG, Giavazzi R, Fojo T.
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [Abstract] [Full Text] [Related]

  • 4. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
    George JA, Chen T, Taylor CC.
    Cancer Res; 2005 Nov 15; 65(22):10381-8. PubMed ID: 16288028
    [Abstract] [Full Text] [Related]

  • 5. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E.
    Mol Pharmacol; 1997 Oct 15; 52(4):613-22. PubMed ID: 9380024
    [Abstract] [Full Text] [Related]

  • 6. Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry.
    Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA, Horwitz SB.
    Biochemistry; 2003 May 13; 42(18):5349-57. PubMed ID: 12731876
    [Abstract] [Full Text] [Related]

  • 7. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T.
    Biochemistry; 2004 Nov 09; 43(44):13944-54. PubMed ID: 15518543
    [Abstract] [Full Text] [Related]

  • 8. Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
    Ranganathan S, McCauley RA, Dexter DW, Hudes GR.
    Br J Cancer; 2001 Sep 01; 85(5):735-40. PubMed ID: 11531260
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
    Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T.
    Oncogene; 2000 Jun 22; 19(27):3078-85. PubMed ID: 10871860
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
    Goto T, Takano M, Sakamoto M, Kondo A, Hirata J, Kita T, Tsuda H, Tenjin Y, Kikuchi Y.
    Oncol Rep; 2006 May 22; 15(5):1265-71. PubMed ID: 16596196
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
    Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, Cheng WF.
    Biochem J; 2009 Dec 10; 424(3):449-58. PubMed ID: 19747165
    [Abstract] [Full Text] [Related]

  • 18. Characterization of nuclear betaII-tubulin in tumor cells: a possible novel target for taxol.
    Xu K, Ludueña RF.
    Cell Motil Cytoskeleton; 2002 Sep 10; 53(1):39-52. PubMed ID: 12211114
    [Abstract] [Full Text] [Related]

  • 19. Differential sensitization by orobol in proliferating and quiescent human ovarian carcinoma cells.
    Shiotsuka S, Isonishi S.
    Int J Oncol; 2001 Feb 10; 18(2):337-42. PubMed ID: 11172601
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.